Skip to main content

Table 1 The characteristics and clinical data of patients with schizophrenia and the control participants

From: Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

 

Schizophrenia patients

Control participants

  

N = 329

N = 175

N

%

N

%

χ2

P

Female

134

40.7

81

46.3

1.44

0.230

Married

95

30.1

139

82.7

126.05

< 0.001

Current smokers

97

29.7

44

25.1

3.90

0.272

Insulin resistance

103

31.9

43

24.7

2.81

0.094

MAO phenotype

52

15.8

16

9.1

4.35

0.037

MHNW phenotype

31

9.4

26

14.9

3.36

0.067

Food intake

 I

98

30.3

24

14.6

14.29

< 0.001

 II

225

69.7

140

85.4

  
 

Mean

SD

Mean

SD

Z/t

P

Age (years)

45.23

11.72

46.08

13.33

−0.82

0.410

Education (years)

8.11

3.63

9.46

3.79

−3.69

< 0.001

BMI (kg/m2)

24.12

3.84

23.45

3.16

1.96

0.049

Glucose (mmol/l)

5.36

1.36

5.33

1.08

−0.37

0.711

Cholesterol (mmol/l)

4.76

1.41

4.58

0.89

−0.89

0.373

Triglycerides (mmol/l)

2.24

1.51

1.63

1.06

−6.08

< 0.001

HDL _C (mmol/l)

1.05

0.27

1.16

0.27

−4.75

< 0.001

LDL_C (mmol/l)

2.40

0.63

2.23

0.53

2.97

0.003

C-peptide (ng/ml)

2.75

1.14

2.54

1.32

−2.79

0.005

Insulin (mU/L)

9.48

8.08

8.69

8.29

−1.81

0.070

HOMA-IR

2.37

2.97

2.20

3.00

−1.57

0.116

  1. MAO phenotype Metabolically abnormal obese phenotype, MHNW phenotype Metabolically healthy normal-weight phenotype, BMI Body mass index, HDL_C High-density lipoprotein cholesterol, LDL_C Low-density lipoprotein cholesterol, insulin resistance HOMA-IR ≥ 2.5, HOMA-IR Homeostasis model assessment of insulin resistance
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us